Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,884,410 papers from all fields of science
Search
Sign In
Create Free Account
Thaliblastine
Known as:
Taliblastine
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Thalicarpine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Antiproliferative activity of the non-myelotoxic antitumour agent of plant origin, Thaliblastine, on two human glioma cell lines
D. Todorov
,
W. Zeller
Journal of Cancer Research and Clinical Oncology
2005
Corpus ID: 22307800
SummaryThe antiproliferative activity of the non-myelotoxic antitumour agent of plant origin, Thaliblastine, on two human glioma…
Expand
2005
2005
Cell cycle effects of thaliblastine
F. Seifert
,
D. Todorov
,
K. Hutter
,
W. Zeller
Journal of Cancer Research and Clinical Oncology
2005
Corpus ID: 20315170
The non-myelotoxic antitumor drug thaliblastine (thalicarpine, NSC-68075, CAS-5373-42-21) has a novel chemical structure; it is a…
Expand
1996
1996
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
G. Chen
,
B. Teicher
,
E. Frei
Anticancer Research
1996
Corpus ID: 20626202
The reversing effect of p-glycoprotein (Pgp) inhibitors on the multidrug resistance (MDR) phenotype is well established in a…
Expand
1995
1995
Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not…
G. Chen
,
D. Waxman
Journal of Pharmacology and Experimental…
1995
Corpus ID: 22753684
The emergence of drug resistance is a major obstacle to effective cancer chemotherapy. The identification of novel agents that…
Expand
1993
1993
Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein.
G. Chen
,
C. Ramachandran
,
A. Krishan
Cancer Research
1993
Corpus ID: 27004980
The effect of thaliblastine (TBL, NSC-68075), a plant alkaloid, in over-coming multidrug resistance was investigated in…
Expand
1993
1993
Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
G. Chen
,
W. Zeller
,
D. Todorov
Anticancer Research
1993
Corpus ID: 35816016
Drug resistance severely limits the effectiveness of clinical cancer chemotherapy. Employment of drugs other than the selected…
Expand
1982
1982
Incorporation of the antitumor alkaloid thaliblastine in liposomes enhances its cytotoxic activity in vitro
D. Todorov
,
G. Deliconstantinos
Experientia
1982
Corpus ID: 9598576
The incorporation of the antitumor alkaloid thaliblastine in liposomes greatly enhances its cytotoxicity in Walker S and TLX-5…
Expand
1980
1980
Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
J. Stoychkov
,
A. S. Miloushev
Biomedicine / [publiee pour l'A.A.I.C.I.G.]
1980
Corpus ID: 20130503
Cyclophosphamide (CY) was tested in combination with the thalictrum alkaloid named thaliblastine (TBL) for therapeutic activity…
Expand
1977
1977
[Toxicological characteristics of thaliblastine[].
I. Mircheva
,
I. Stoichkov
Farmakologiia i toksikologiia
1977
Corpus ID: 27493211
The toxic action of the antiphlogistic drug thaliblastin, containing 93-95 per cent of the alcaloid thalicarpine was investigated…
Expand
1976
1976
Effect of thaliblastine on transplantable tumours in mice.
J. Mircheva
,
J. Stoychkov
Biomedicine / [publiee pour l'A.A.I.C.I.G.]
1976
Corpus ID: 20450213
The antitumour activity of the alkaloid thaliblastine was studied on 7 ascitic and solid transplantable tumours in mice. It was…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE